A strategic partnership agreement between Kaluga pharmaceutical cluster and Pharmcontract Group, a leading Russian chemical and pharmaceutical holding company, was officially signed on April 4 at PharmEvolution 2017, an international forum.
Over the years of its existence, Kaluga pharmaceutical cluster demonstrated that the companies – members of the cluster, have a strong innovation, research and industrial potential. Today, the cluster comprises 63 enterprises and organizations, 38 small-sized innovation and design companies.
The signed agreement provides for a partnership that spans a wide range of formats in the area of scientific development of the industry and specific areas of specialization of the companies participating in the pharmaceutical cluster. In addition, it provides for joint participation in the development, creation and support of innovative manufacturing technologies aimed primarily at import substitution in the pharmaceutical, chemical and biotech industries by investing in R&D and industrial works, programs and special projects. The partnership is concluded for a five-year period and can be extended further. Moreover, with such partnership, the participants of pharmaceutical cluster can count on special terms, additional preferences and, of course, discount programs for supplies of high-tech equipment, construction and installation of production lines in pharmaceutical companies of Kaluga region.